A detailed history of Manchester Capital Management LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Manchester Capital Management LLC holds 1,000 shares of CRSP stock, worth $50,840. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$50,840
Previous $54,000 14.81%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$38.62 - $72.18 $38,620 - $72,180
1,000 New
1,000 $62,000
Q1 2022

May 09, 2022

SELL
$53.19 - $79.24 $42,552 - $63,391
-800 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$110.72 - $210.04 $13,729 - $26,044
-124 Reduced 13.42%
800 $97,000
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $73,615 - $160,064
924 New
924 $141,000
Q2 2019

Aug 05, 2019

SELL
$35.45 - $48.2 $7,799 - $10,604
-220 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$28.02 - $40.87 $6,164 - $8,991
220 New
220 $8,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Manchester Capital Management LLC Portfolio

Follow Manchester Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manchester Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Manchester Capital Management LLC with notifications on news.